Form 4: Glaukos Director Leana Wen Receives Equity Grant

Director Leana Wen acquired 1,878 restricted stock units and 2,987 stock options as part of the Glaukos Corporation director compensation policy.

Summary

• Director Leana Wen was granted 1,878 restricted stock units (RSUs) on May 28, 2026.
• Director Leana Wen was granted 2,987 stock options with an exercise price of $53.57 on May 28, 2026.
• The total beneficial ownership for the director following these transactions is 21,617 shares.
• The equity grants are part of the standard Glaukos Corporation Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation with no impact on company operations.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized compensation structure indicates stable corporate governance practices.

Negatives

• None identified; this is a routine disclosure of director compensation.

Risks

• Market price volatility affecting the value of the granted options and RSUs.

Future Outlook

The equity grants vest in full on the one-year anniversary of the grant date, May 28, 2027.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard practice in the medical device and biotechnology sectors to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The compensation structure is consistent with standard practices for mid-cap medical device companies.
• Equity-based compensation for directors is a common benchmark for companies like Glaukos to retain board talent.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as these are standard director compensation grants.

Next Steps

• Vesting of the granted RSUs and options on May 28, 2027.

Key Dates

Keywords

Glaukos, GKOS, Director Compensation, Form 4, Insider Trading, Equity Grant